Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment. / Wanner, Christoph; Feldt-Rasmussen, Ulla; Ortiz, Alberto.
I: Future Cardiology, Bind 18, Nr. 10, 2022, s. 755-763.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment
AU - Wanner, Christoph
AU - Feldt-Rasmussen, Ulla
AU - Ortiz, Alberto
N1 - Publisher Copyright: © 2022 The Authors.
PY - 2022
Y1 - 2022
N2 - What is Fabry disease & what is this study about? Fabry disease is a rare genetic condition that affects many different cells and organs in the body. People have Fabry disease when they inherit a GLA gene containing an error from one or both of their parents. This causes an enzyme in their body called alpha-galactosidase (also called α-Gal) to not work properly. In people without Fabry disease, a-Gal breaks down fats called glycolipids. In people with Fabry disease, as a-Gal does not work properly, glycolipids build up in the body, particularly in the cells of the kidney, heart, nerves, and the cells that line blood vessels. People who have Fabry disease can receive an enzyme replacement therapy (ERT for short) called agalsidase beta, which acts as a substitute for a-Gal. Although both males and females can have Fabry disease, it generally affects males more severely than females, and symptoms in females can vary significantly. Several researchers have studied the long-term effects of agalsidase beta ERT in males, but there have been fewer studies in females. This study looked at women with Fabry disease who started receiving agalsidase beta treatment when they were at least 18 years old, using information from the Fabry Registry (the largest worldwide database that collects and stores information about people with Fabry disease). The researchers evaluated heart muscle thickness (thickening can be a sign of poor heart health) and kidney function from 5 years before women with Fabry disease started agalsidase beta treatment to 5 years after they started treatment. What were the study results? Before women with Fabry disease started treatment, their heart muscle tended to thicken over time. After starting treatment, their heart muscle thickening slowed. Kidney function was similar to that of unaffected people both before and after treatment. What do the results of the study mean? This study provides a unique insight into the effects of agalsidase beta in women with Fabry disease. The findings suggest that agalsidase beta may slow heart muscle thickening and maintain normal kidney function in women with Fabry disease. Clinical Trial Registration: NCT00196742 (ClinicalTrials.gov)
AB - What is Fabry disease & what is this study about? Fabry disease is a rare genetic condition that affects many different cells and organs in the body. People have Fabry disease when they inherit a GLA gene containing an error from one or both of their parents. This causes an enzyme in their body called alpha-galactosidase (also called α-Gal) to not work properly. In people without Fabry disease, a-Gal breaks down fats called glycolipids. In people with Fabry disease, as a-Gal does not work properly, glycolipids build up in the body, particularly in the cells of the kidney, heart, nerves, and the cells that line blood vessels. People who have Fabry disease can receive an enzyme replacement therapy (ERT for short) called agalsidase beta, which acts as a substitute for a-Gal. Although both males and females can have Fabry disease, it generally affects males more severely than females, and symptoms in females can vary significantly. Several researchers have studied the long-term effects of agalsidase beta ERT in males, but there have been fewer studies in females. This study looked at women with Fabry disease who started receiving agalsidase beta treatment when they were at least 18 years old, using information from the Fabry Registry (the largest worldwide database that collects and stores information about people with Fabry disease). The researchers evaluated heart muscle thickness (thickening can be a sign of poor heart health) and kidney function from 5 years before women with Fabry disease started agalsidase beta treatment to 5 years after they started treatment. What were the study results? Before women with Fabry disease started treatment, their heart muscle tended to thicken over time. After starting treatment, their heart muscle thickening slowed. Kidney function was similar to that of unaffected people both before and after treatment. What do the results of the study mean? This study provides a unique insight into the effects of agalsidase beta in women with Fabry disease. The findings suggest that agalsidase beta may slow heart muscle thickening and maintain normal kidney function in women with Fabry disease. Clinical Trial Registration: NCT00196742 (ClinicalTrials.gov)
KW - agalsidase beta
KW - cardiomyopathy
KW - enzyme replacement therapy
KW - Fabry disease
KW - female patients
KW - kidney function
KW - lay summary
KW - plain language summary
U2 - 10.2217/fca-2022-0047
DO - 10.2217/fca-2022-0047
M3 - Journal article
C2 - 36073247
AN - SCOPUS:85140273842
VL - 18
SP - 755
EP - 763
JO - Future Cardiology
JF - Future Cardiology
SN - 1479-6678
IS - 10
ER -
ID: 329205145